TTX-030
Based on 1 Customer Validation
TTX-030 (Eltivutabart) is a monoclonal antibody that allosterically inhibits CD39 ectonucleotidase activity, preventing the conversion of ATP to AMP. TTX-030 acts as a non-competitive allosteric CD39 ATPase inhibitor, binding to an N-terminal epitope distant from the active site and blocking nucleotide hydrolysis. TTX-030 has an IC50 of 0.20 nM, a Kd of 1.5 nM, and a Ki of 0.5 nM for human CD39. TTX-030 enhances CD4+ and CD8+ T cell proliferation, Th1 cytokine production, T cell function, dendritic cell maturation, and inflammasome activation. TTX-030 can be used in research on human B cell lymphoma and cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.34%
- CAS No.: 2935496-38-9
- 분자량:150 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
|
CD39 0.2 nM (IC50) |
CD39 1.5 nM (Kd) |
CD39 0.5 nM (Ki) |
In Vitro
TTX-030 (60 min) non-competitively inhibits CD39 ATPase in SK-MEL-28 cells with a Ki of 0.50 nM and a maximum inhibition rate of up to 85%, and maintains its inhibitory effect under washing, repeated ATP addition, and pH 6.5 conditions[2].
TTX-030 inhibits CD39-mediated Pi release in primary human B cells[2].
TTX-030 (200 ng/mL; 30 min) inhibits SK-MEL-28 CD39-mediated sequential hydrolysis of 3HATP to adenosine[2].
TTX-030 (0.5 μg/mL; 45 min) almost completely blocks CD39-mediated ADPase activity in human tonsils[2].
TTX-030 (15 µg/mL; 30 min) binds cell surface CD39 with 100-500 pM affinity, selectively recognizes human and cynomolgus monkey CD39, and localizes to an allosteric epitope at E142-Y159[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
TTX-030 (250 μg per dose; intraperitoneal injection; days 5, 8, 11, and 14; four doses in total) combined with Pembrolizumab (HY-P9902) and autologous EBV-specific T cells exhibits stronger inhibition of LCL043 tumor growth than either antibody combined with T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-RAG1-gamma c (NRG) (immunodeficient)[2]
-
Dosage:250 μg per dose
-
Administration:i.p.; days 10, 13, 16, and 19; four doses total
-
Result:Was without effect against LCL039 tumors as monotherapy.
Autologous EBV-specific T cells were more active alone in this setting; the antitumor activity of autologous EBV-specific T cells was enhanced.
At endpoint day 23, increased the percentage of tumor-infiltrating CD3+ cells and the number of tumor-infiltrating CD3+CD8+ T cells compared with cIg control mice.
Decreased CD39 expression levels on intratumor CD8+ T cells compared with cIg control.
PD-1 expression was increased on CD8+ T cells after injection; PD-1 expression levels on intratumor CD8+ T cells were reduced compared with cIg control.
IHC on day 23 LCL039 tumors showed increased CD8+ T-cell infiltration and reduced CD39 expression in the EBV-specific T-cell combination tumors.
-
Animal Model:NOD-RAG1-gamma c (NRG) (immunodeficient)[2]
-
Dosage:250 μg
-
Administration:i.p.; days 5, 8, 11, and 14; four doses total
-
Result:The combination with Pembrolizumab and T-cell transfer produced an even greater effect on tumor growth.
- Naïve CD4+ T-cell subset differentiation/polarization
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Research Protocol for Inflammation-related Diseases
- Colony Formation (Clonogenic) Assay
- Research Protocol for Cancer Immunology
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- MTT Cell Proliferation Assay
- Pyroptosis Solutions
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD39 Protein, Human can bind Eltivutabart. The EC50 for this effect is 37.12 ng/mL. -
Flow Cytometry analysis of Raji cells labelling ENTPD1/CD39 (red) with TTX-030 (anti-ENTPD1/CD39) (HY-P990670). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 kappa (HY-P99003). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 2935496-38-9
-
Appearance Liquid
-
분자량 150 kDa
-
Color Colorless to light yellow
-
Synonyms
Eltivutabart
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TTX-030 Related Classifications
HY-P990670 Related Classifications
Powered by Bioz